文献速递分子诊断临床微生物临床免疫

院内金氏菌PCR在大型儿科队列中的应用:对诊断、抗菌药物管理和临床结局的影响

An in-house Kingella kingae PCR in a large pediatric cohort: impact on diagnosis, antimicrobial stewardship, and clinical outcomes.
PubMed 文献 · J Clin Microbiol · 2025-10-09

本研究回顾性分析了2014年9月至2024年1月期间在Nationwide儿童医院接受院内金氏菌PCR(KKIN PCR)检测的≤18岁患者,共500例有完整数据,其中46例检出金氏菌。与临床诊断相比,KKIN PCR的灵敏度、特异度、阳性预测值和阴性预测值分别为95.7%、100%、100%和99.6%。在≤5岁患儿中,金氏菌是最常见的检出病原体。KKIN PCR的中位报告时间为26.5小时,38例(84%)在报告后1天内调整了抗菌药物,实现了降阶梯或优化治疗。研究表明,常规使用院内KKIN PCR显著提高了儿科骨关节感染的诊断率,促进了及时靶向治疗并改善了管理。

要点

  • KKIN PCR灵敏度95.7%、特异度100%,显著优于培养。
  • 80%病例仅由PCR检出,较培养提高四倍。
  • 84%患者在报告后1天内优化抗菌治疗。

核心结论

  • 常规使用院内KKIN PCR可显著提高儿科骨关节感染的诊断率,促进及时靶向治疗并改善管理。

研究设计与样本

  • 回顾性研究,纳入2014年9月1日至2024年1月31日在Nationwide儿童医院接受KKIN PCR检测的≤18岁患者,共500例有完整数据。

主要发现

  • 与临床诊断相比,KKIN PCR灵敏度95.7%、特异度100%、阳性预测值100%、阴性预测值99.6%。
  • ≤5岁患儿中金氏菌是最常见检出病原体。
  • KKIN PCR中位报告时间26.5小时,38例(84%)在报告后1天内调整抗菌药物。

关键数值与推荐

  • 灵敏度95.7%、特异度100%、阳性预测值100%、阴性预测值99.6%。
  • 中位报告时间26.5小时。
  • 38例(84%)在报告后1天内进行抗菌药物调整。

临床怎么用

  • 对≤5岁疑似骨关节感染的患儿,可常规送检院内KKIN PCR以提高病原检出。
  • PCR快速报告(中位26.5小时)有助于及时降阶梯或优化抗菌治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Kingella kingae is a bacterial pathogen associated with bone and joint infections and a major pathogen in pediatric populations, particularly in those ≤5 years of age. Molecular detection methods have demonstrated significant increases in sensitivity compared to culture, allowing rapid and accurate identification. The objective of this study was to characterize the performance of an in-house K. kingae PCR (KKIN PCR) and determine its impact on antimicrobial utilization and clinical management in a pediatric population. Laboratory records from 1 September 2014 to 31 January 2024 were reviewed to identify subjects ≤18 years old who had KKIN PCR testing performed at Nationwide Children's Hospital. Demographics, symptoms, radiologic and laboratory findings, hospitalization status, antimicrobial therapy, and clinical outcomes were analyzed. During the study period, 500 unique subjects with KKIN PCR ordered had complete data available, among whom 46 had K. kingae detected by PCR or culture. Compared to the clinical diagnosis, KKIN PCR had sensitivity, specificity, and positive and negative predictive values of 95.7, 100, 100, and 99.6%, respectively. Thirty-six (80%) subjects were detected by PCR alone, improving case identification by fourfold compared to culture (n = 9). Among subjects ≤5 years old, K. kingae was the most common organism detected. The median time to result for KKIN PCR was 26.5 h, and 38 (84%) subjects had antimicrobial modifications within 1 day of KKIN PCR report, resulting in de-escalation or antimicrobial optimization. This study demonstrates that routine use of in-house KKIN PCR significantly increased the diagnosis, facilitated timely and targeted treatment, and improved management of pediatric bone and joint infections.IMPORTANCEKingella kingae (KKIN) has long been recognized as a major cause of bone and joint infections in pre-school aged children. However, diagnosis and prevalence of KKIN infection are underestimated due to poor culture recovery. Previous studies have shown that molecular-based methods improve KKIN detection compared to culture, but these methods are not widely implemented or routinely used in clinical microbiology laboratories. This study describes the performance and clinical utility of an in-house laboratory-developed KKIN PCR in a large pediatric cohort over a nearly 10-year period. In addition to demonstrating improved KKIN detection compared to culture, it also shows that rapid availability of in-house KKIN PCR facilitated timely antimicrobial de-escalation and potentially contributed to shortened hospital length of stay compared to previous reports. This study highlights a critical diagnostic gap that can be alleviated with a validated laboratory-developed PCR to improve diagnosis and management of KKIN infections.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Oyeniran SJ, Leber AL, Wang H, et al. An in-house Kingella kingae PCR in a large pediatric cohort: impact on diagnosis, antimicrobial stewardship, and clinical outcomes. J Clin Microbiol. 2025. PMID: 41065397. doi:10.1128/jcm.00986-25

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。